TitleVisiting Assistant Professor of Chemistry and Biochemistry
For most of his scientific career, Brian Reed has been conducting work in interdisciplinary studies related to the consequences of exposure to drugs of abuse such as cocaine and opioids. He studied predominantly chemistry (analytical chemistry, organic chemistry, and biochemistry) prior to joining the multidisciplinary Laboratory of the Biology of Addictive Diseases at Rockefeller University. At Rockefeller he had the opportunity to diversify his skills and research foci to other aspects of the science of Addiction Medicine, including clinical studies, genetic and epigenetic studies, animal behavior and endocrinology, and drug discovery efforts to develop novel medications.
He is an elected representative to the Executive Committee of the International Narcotics Research Conference, and has published both independently as well as with many mentored post-doctoral fellows, graduate students, research students, and undergraduate summer students. He is actively engaged in national and international collaborations with colleagues in California, Italy, and other locales.
Ph.D., Chemistry, Emory University
B.A., Chemistry, Vassar College
Reed B, Miller M, Michino M, Butelman ER, Ben-Ezra A, Pikus P, Morochnik M, Kim Y, Ripka A, Vacca J, Kreek MJ. (2022) Characterization of Pyrrolidinyl-hexahydro-pyranopiperazines as a Novel Kappa Opioid Receptor Agonist Scaffold. ACS Chem Neurosci. 13:1849-1856. (https://pubmed.ncbi.nlm.nih.gov/35738565/)
Reed B, Kreek MJ (2020) Genetic vulnerability to opioid addiction. Cold Spring Harbor Perspectives in Medicine, Addiction, 2nd Ed., Eds. Pierce RC, Unterwald EM, and Kenny PJ, Cold Spring Harbor Laboratory Press, New York, pp123-136. (https://pubmed.ncbi.nlm.nih.gov/32205416/)
Miller MW, Reed B (2020) Recent progress in kappa and mu opioid receptor targeted ligands. Medicinal Chem Reviews, 55, 102-116.)
Kreek MJ, Reed B, Butelman ER (2019) Current status of opioid addiction treatment and related preclinical research. Science Advances, 5:eaax9140. (https://pubmed.ncbi.nlm.nih.gov/31616793/)
Reed B*, Butelman ER*, Fry RS, Kimani R, Kreek MJ (2018) Repeated administration of Opra Kappa (LY2456302), a novel, short-acting, selective KOP-r antagonist, in persons with and without cocaine dependence. Neuropsychopharmacol. 43:739-750. (https://pubmed.ncbi.nlm.nih.gov/28857070/)
Drugs and the Brain